July 25, 2019
Blueprint Medicines
Blueprint Medicines to Report Second Quarter 2019 Financial Results on Thursday, August 1, 2019
July 25, 2019
Editas Medicine
Allergan and Editas Medicine Initiate the Brilliance Phase 1/2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10
July 25, 2019
TARIS Bio
TARIS Announces Presentation of Clinical Data for TAR-302 For Overactive Bladder
July 24, 2019
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Announces Appointment of Stuart Arbuckle to its Board of Directors
July 24, 2019
Sage Therapeutics
Sage Therapeutics Announces Clinical Updates and Progress Across Neuroscience Pipeline During “Sage FutureCast”